Eagle Pharmaceuticals Inc. (EGRX) began trading on the NASDAQ on 12 February 2014

Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) held its IPO on Wednesday. The company focuses on developing injectable products primarily the areas of critical care and oncology. The company offered 3.35 million shares at $15 a share, the midpoint of its expected range of $14 to $16. At that price the company has a market value of around $216 million. Shares closed at $12.83 on Wednesday and at $12.80 on Friday.

Description

Eagle Pharmaceuticals, Inc. (Eagle Pharmaceuticals) is a specialty pharmaceutical company. The Company focused on developing and commercializing injectable products. The Company develops products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially injectable products. Its two most advanced product candidates are EP-3101 (bendamustine RTD), a intravenous version of the chemotherapeutic agent that is marketed by Teva under the brand name Treanda, and Ryanodex (dantrolene for MH), a intravenous version of an approved treatment for malignant hyperthermia. The Company’s products include EP-3101, EP-3102, Ryanodex, EP-4104, EP-6101, EP-5101, EP-1101 and EP-2101.

Address

SUITE 315, 50 TICE BOULEVARD
WOODCLIFF LAKE, NJ 07677
United States

Website 

http://www.eagleus.com

Key stats and ratios

	Q4 (Dec '13)	2013
Net profit margin	-59.28%	-44.22%
Operating margin	-55.82%	-61.81%
EBITD margin	-	-60.82%
Return on average assets	-72.31%	-43.92%
Return on average equity	-	-
Employees	20